Ceramic Modular Dual Mobility in Primary Total Hip Arthroplasty (THA)
Launched by AESCULAP AG · Sep 16, 2022
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new type of hip implant called a modular dual mobility insert, which is designed to provide better stability and movement for patients undergoing total hip replacement surgery. The trial compares this new insert, which has a special ceramic coating, to the standard type made from polyethylene. The goal is to see which option is better for patients with coxarthrosis, a common hip condition.
To participate in this study, you must be between 65 and 74 years old and have a specific type of hip problem that requires surgery. You should be in good overall health and able to give your consent to join the trial. Unfortunately, if you have certain conditions like severe obesity, ongoing cancer treatment, or have had previous hip trauma or surgeries, you won't be eligible. If you join the study, you will receive one of the two types of implants and will be monitored regularly to see how well it works for you. This trial is currently recruiting participants, and your involvement could help improve hip surgery outcomes for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Primary coxarthrosis patients indicated for cementless total hip arthroplasty
- • Written informed patient consent
- Exclusion Criteria:
- • Hip trauma or revision surgery
- • Rheumatoid or neurologic disease
- • BMI \>35
- • Ongoing oncologic therapy
- • Preoperatively elevated Co or Cr serum levels \>1.0 µg/L
- • Patients with other joint implants, or anticipated need for another joint replacement surgery within the study period
- • Acetabular cup size \<52 expected
- • Patients not able to mentally or physically comply with the study demands and follow-up visits
- • Patients \<18 years at surgery
- • Pregnancy
About Aesculap Ag
Aesculap AG is a prominent global medical device manufacturer specializing in surgical instruments, implants, and innovative healthcare solutions. With a rich history rooted in excellence and innovation, Aesculap AG is dedicated to advancing surgical practices through cutting-edge technology and a commitment to improving patient outcomes. The company collaborates with healthcare professionals and institutions to conduct clinical trials that evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of quality and performance. Through its rigorous research and development initiatives, Aesculap AG aims to contribute significantly to the field of medicine and enhance the standards of surgical care worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
ústí Nad Labem, , Czechia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials